drugset / Trial / NCT07402213

Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

NCT07402213

Phase 3 Not yet recruiting 180 enrolled Jemincare
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase III Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

Timeline

Start
2026-03-31
Primary completion
2027-06-30
Completion
2028-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject OZUREPRUBART Monoclonal antibody 300 mg Subcutaneous